T

Thermo Fisher Scientific

Makes lab instruments, reagents and supplies

RED Program - Engineering Track

Full-Time
No salary listed
Entry
Bachelor's
Terracina, Italy
In PersonOn-site role in Ferentino, Lazio, Italy.
Engineering Management

About the job

Requirements
  • Bachelor's degree in Mechanical, Chemical, Management Engineering or related field
  • Fluent English, written and spoken
  • Exceptional problem-solving skills and ability to think analytically
  • Strong communication and collaboration skills to effectively work with cross-functional teams
  • Motivated and eager attitude with a passion for ongoing growth and development
  • Ability to successfully implement process improvements and drive operational excellence
  • Familiarity with statistical analysis and process control techniques
  • Previous experience in the Pharma industry as long as international experiences will be considered a plus
Responsibilities
  • Three secondments in various functional groups where selected candidates will experience accelerated career opportunities throughout job rotations, having the chance to be part of different teams
  • The ultimate goal is to create formed professionals to work in key teams in Engineering roles.
Desired Qualifications
  • Innovation: Create value by transforming knowledge and ideas into services that have a real impact on our Customer
  • Intensity: Be determined to deliver results with speed, excellence and a passion to succeed
  • Integrity: Honor commitments and demonstrate the highest ethical standards
  • Involvement: Make connections to work as one global team

About the company

T

Thermo Fisher Scientific

View
Website

Thermo Fisher Scientific makes and sells the instruments, chemicals, consumables and lab services that drug companies, hospitals, universities and industrial labs use for research, testing and production. Its products cover work from gene sequencing and protein analysis to diagnostic tests and lab freezers, and its distribution arm ships supplies to labs worldwide. Drug developers also hire it to run clinical trials and to manufacture medicines under contract. It earns money from consumables that labs buy again and again, along with instrument sales, service contracts and outsourcing fees. The company traces its roots to Thermo Electron, founded in 1956, which merged with Fisher Scientific in 2006, and it is based in Waltham, Massachusetts.

Company Size

10,001+

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

1956

Get referred to Thermo Fisher Scientific

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Drugmaker demand is firming: revenue rose 10% to $11.99 billion in the June 2026 quarter, 5% excluding deals and currency.
  • Profits are outpacing sales, which supports stock grants: adjusted earnings per share rose 13% in the June 2026 quarter.
  • Career paths span many businesses: Thermo Fisher runs four segments, from diagnostics to contract drug development.

What critics are saying

  • Factory jobs are shrinking: Thermo Fisher announced in January 2026 it will close its Asheville plant, cutting 421 jobs.
  • Whole units get sold: microbiology, with $645 million in 2025 sales, went to buyout firm Astorg in August 2026.
  • Cuts reach California too: Thermo Fisher filed in January 2026 to lay off 173 Carlsbad workers by March.

What makes Thermo Fisher Scientific unique

  • Many familiar lab brands sit under one roof: Thermo Fisher owns Thermo Scientific, Applied Biosystems, Invitrogen and Fisher Scientific.
  • Thermo Fisher reaches labs through its own sales force of about 14,000 people, per its 2025 annual filing.
  • Its trial-data unit Clario has supported about 70% of FDA and EMA novel drug approvals over the past decade.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Unlimited Paid Time Off
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • 401(k) Retirement Plan
  • 401(k) Company Match

Company News

Yahoo Finance
Oct 29th, 2026
Thermo Fisher named a leader in cell and gene therapy CRO market after $12.1B Q3 sales

Thermo Fisher Scientific (NYSE:TMO) has been highlighted as a leading player in the cell and gene therapy contract research organisation (CRO) market. It offers integrated clinical trial services for advanced therapies as drugmakers outsource more R&D. Demand is tied to growing personalised medicine activity and stricter regulatory demands on complex trials. In its third-quarter 2026 report, the US life sciences group posted sales of $12.1 billion and net income of $1.7 billion. Basic earnings per share from continuing operations were $4.65. Investors are watching whether pharma and biotech services gain weight in Laboratory Products & Biopharma Services, and whether Clario adds revenue.

Yahoo Finance
Oct 29th, 2026
Thermo Fisher shares up 22.1% in 90 days as $12.1B quarterly sales leave stock 3% overvalued

Thermo Fisher Scientific (TMO) reported third quarter 2026 sales of $12.1 billion and net income of $1.7 billion. Its shares have gained 22.1% over 90 days and 18.8% so far this year. One-year total shareholder return stands at 26.6%. At a last close of $704.15, the stock trades about 3% above the $686.64 fair value set by the most followed narrative. Its price-to-earnings ratio of 36.8x compares with a fair ratio of 34.6x, a Global Life Sciences average of 38.1x, and a peer average of 40.1x. Risks include muted academic and government funding, and a longer drag on earnings from the microbiology divestiture.

Yahoo Finance
Oct 28th, 2026
Teen wins $25K for low-cost airborne bacteria sampler at Thermo Fisher Junior Innovators Challenge

Bailey Quinn Frank, 15, of Fort Lauderdale, Florida, won the $25,000 Thermo Fisher Scientific ASCEND Award, the top prize at the 2026 Thermo Fisher Scientific Junior Innovators Challenge. Thermo Fisher Scientific and Society for Science announced the winners in Washington, D.C. Frank built a low-cost environmental DNA sampler that uses a small fan and filter paper to collect airborne bacteria. She says it could help rural communities monitor health threats where resources for disease surveillance are limited. The 30 finalists, chosen from nearly 2,000 applicants, shared more than $100,000 in awards. Four other top winners each received $10,000, including twin brothers Henry and Jack Grover, 14, who developed a hydrogel sprayer to stop wildfires reigniting.

Yahoo Finance
Oct 23rd, 2026
Illumina stock is up 172.2% in a year, but is Thermo Fisher the cheaper buy?

Illumina and Thermo Fisher Scientific both sell to drug developers and patient-testing labs, but their financial profiles split evenly. Illumina stock returned 172.2% over the past year, against 21.7% for Thermo Fisher. Illumina raised its 2026 revenue forecast to a midpoint of $4.62 billion on July 30, driven by clinical markets. Thermo Fisher raised its 2026 guidance on October 21 to $47.7 billion–$48.2 billion, after third-quarter revenue rose 9% to $12.14 billion. Illumina leads on margins and debt: a 66.4% gross margin against 40.8%, and debt equal to 6.2% of market value against 17.0%. Thermo Fisher leads on price and growth. Illumina trades at 49.3 times trailing earnings, against 36.0 for Thermo Fisher, which also grew revenue 7.2% against 4.9%.

Yahoo Finance
Oct 22nd, 2026
Thermo Fisher Q3 revenue rises 9.1% to $12.14B, beating estimates on pharma and AI

Thermo Fisher beat Wall Street expectations in the third quarter of 2026, with sales up 9.1% year on year to $12.14 billion. Analysts had expected $11.96 billion. Adjusted earnings per share were $6.68, 4.3% above the $6.40 estimate. Operating margin rose to 18.6% from 17.5% a year earlier, and organic revenue grew 6%. Chief executive officer Marc Casper credited a broad recovery in end markets, high single-digit growth in pharma services, and strong electron microscopy demand from the semiconductor industry. Asia Pacific posted low double-digit growth. The company expects further momentum in pharma services and clinical research, and plans to integrate AI across its products. Bioscience reagents remain soft. Shares trade at $697.65, up from $687.37 before the results.